MARK J. ALVINO - Corporate Board Profile

ABEONA THERAPEUTICS INC.

Filing Date	Source Excerpt
2007-04-13	Mr. Mark J. Alvino became a director in March 2006 as a designee of SCO Capital Partners LLC. ... The Nominating and Corporate Governance Committee is currently comprised of John J. Meakem, Jr. (chairman) and Mark J. Alvino. ... The table below represents the compensation paid to our directors during the year ended December 31, 2006: Mark J. Alvino: Fees earned or Paid in Cash ($) 13,000, Option Awards ($) 5,581, Total ($) 18,581.
2008-04-22	Mr. Mark J. Alvino became a director in March 2006 initially as a designee of SCO Capital Partners LLC and is a member of the Nominating and Corporate Governance Committee. ... Director Compensation Table - 2007: Mark J. Alvino total compensation $16,000.
2009-04-22	Mr. Mark J. Alvino became a director in March 2006 initially as a designee of SCO Capital Partners LLC and is a member of the Nominating and Corporate Governance Committee. ... Mark J. Alvino Fees earned or Paid in Cash ($) 16,000 Option Awards ($)(1) 16,000 Total ($) 32,000.
2010-04-16	Mr. Mark J. Alvino became a director in March 2006 initially as a designee of SCO Capital Partners LLC and is chairman of the Audit and Finance Committee. Mr. Alvino is also a member of the Nominating and Corporate Governance Committee. ... Mr. Alvino has options to purchase 66,000 shares of our Common Stock at December 31, 2009.
2011-04-14	Mark J. Alvino, a Director, is chairman of the Audit Committee and member of the Nominating and Corporate Governance Committee. Represents expense recognized in 2010 in respect of options to purchase 30,000 shares of our common stock based on a grant date fair value of $64,000.
2012-04-16	The Audit Committee is currently comprised of Mr. Mark J. Alvino (chairman) and Mr. Mark J. Ahn. The Nominating and Corporate Governance Committee is currently comprised of Mark Ahn, PhD and Mark J. Alvino. Mr. Alvino received options to purchase 35,000 shares of our common stock based on a grant date fair value of $67,000.
2013-04-02	Mr. Mark J. Alvino became a director in March 2006 initially as a designee of SCO Capital Partners LLC and is chairman of the Audit Committee. He is no longer a designee of SCO Capital Partners LLC. Mr. Alvino is also a member of the Nominating and Corporate Governance Committee. Mr. Alvino is currently Managing Director for Griffin Securities and has been in this position since 2007. Mr. Alvino was Managing Director for SCO Financial Group LLC from 2002 to 2007. Mr. Alvino was a member of the board of directors of MacroChem Corporation from 2007 until February 2009. He previously worked at Feinstein Kean Healthcare, an Ogilvy Public Relations Worldwide Company. There he was Senior Vice President, responsible for managing both investor and corporate communications programs for many private and public companies and acted as senior counsel throughout the agency's network of offices. Prior to working at FKH, Mr. Alvino served as Vice President of Investor Relations and managed the New York Office of Allen & Caron, Inc., an investor relations agency. His base of clients included medical devices, biotechnology, and e-healthcare companies. Mr. Alvino also spent several years working with Wall Street brokerages including Ladenburg, Thallman & Co. and Martin Simpson & Co. Mr. Alvino’s qualifications to serve our Board include his leadership skills and his experience in the areas of financial management and business strategy in the biopharmaceutical field.
2014-04-15	Mr. Mark J. Alvino became a director in March 2006 initially as a designee of SCO Capital Partners LLC and is chairman of the Audit Committee. He is no longer a designee of SCO Capital Partners LLC. Mr. Alvino is also a member of the Nominating and Corporate Governance Committee.
2015-04-07	Mark J. Alvino 47 Director ... Mr. Alvino is chairman of the Audit Committee. He is also a member of the Nominating and Corporate Governance Committee. ... The table below represents the compensation paid to our outside directors during the year ended December 31, 2014: Mark J. Alvino 69,000 ... Mr. Alvino became a director in March 2006 initially as a designee of SCO Capital Partners LLC.
2016-04-06	Mr. Alvino is chairman of the Audit Committee. ... Mr. Alvino is also a member of the Compensation Committee and Nominating and Corporate Governance Committees. ... Mr. Alvino received total compensation of $890,000 in 2015.
2017-04-11	Mark J. Alvino, 49, became a director in March 2006 initially as a designee of SCO Capital Partners LLC and is chairman of the Audit Committee. ... The Audit Committee is currently comprised of Mark J. Alvino (Chairman) and Todd Wider, M.D. ... The Compensation Committee is currently comprised of Stephen B. Howell, M.D. and Mark J. Alvino. ... The Nominating and Corporate Governance Committee is currently comprised of Mark J. Alvino and Stephen B. Howell, M.D. ... The table below represents the compensation paid to our outside directors during the year ended December 31, 2016: ... Mark J. Alvino ... Total ($) 306,000
2018-04-10	Mark J. Alvino 50 Director The Audit Committee is currently comprised of Mark J. Alvino (Chairman), Stephen B. Howell, M.D. and Todd Wider, M.D. The Compensation Committee is currently comprised of Stephen B. Howell, M.D. and Mark J. Alvino. The Nominating and Corporate Governance Committee is currently comprised of Mark J. Alvino and Stephen B. Howell, M.D. Director Compensation Table — 2017 The table below represents the compensation paid to our outside directors during the year ended December 31, 2017: Mark J. Alvino Fees earned or Paid in Cash ($) 40,000 Bonus ($) — Stock Awards ($) — Option Awards ($)(1) 380,000 Total ($) 420,000(2)
2019-04-11	Mark J. Alvino, 51, became a director in March 2006 initially as a designee of SCO Capital Partners LLC and serves as Chair of the Audit Committee and the Compensation Committee.
2020-04-10	Mark J. Alvino, 52, Director
2021-04-09	Mark J. Alvino, 53, became a director on March 26, 2021 and currently serves as Chair of the Compensation Committee and as a member on the Audit Committee.
2022-05-12	Mark J. Alvino is listed as a Director and Named Executive Officer with beneficial ownership of shares but no specific age, committees, or compensation details are provided.
2022-07-11	Mark J. Alvino, 54, became a director on March 26, 2021 and currently serves as Chair of the Compensation Committee and as a member on the Audit Committee. Mr. Alvino had previously served as a member of our Board from March 2006 through April 15, 2020. Mr. Alvino is currently President of Hudson Square Capital LLC, since October 2014. From 2013 to October 2014, Mr. Alvino was leading the Life Sciences efforts of Bradley Woods & Co. Ltd. Mr. Alvino was Managing Director for Griffin Securities from 2007 to 2013. He previously worked at Feinstein Kean Healthcare, an Ogilvy Public Relations Worldwide Company, where he was Senior Vice President, responsible for managing both investor and corporate communications programs for many private and public companies and acted as senior counsel throughout the agency’s network of offices. Prior to working at FKH, Mr. Alvino served as Vice President of Investor Relations and managed the New York Office of Allen & Caron, Inc., an investor relations agency. His base of clients included medical devices, biotechnology, and e-healthcare companies. Mr. Alvino also spent several years working with Wall Street brokerages including Ladenburg, Thallman & Co. and Martin Simpson & Co. Mr. Alvino’s qualifications to serve on our Board include his leadership skills and his experience in the areas of financial management and business strategy in the biopharmaceutical field.
2023-04-13	Mark J. Alvino, 55, became a director on March 26, 2021 and currently serves as Chair of the Compensation Committee and as a member on the Audit Committee. ... Mark J. Alvino 65,000 37,386 102,386
2024-03-19	Mark J. Alvino 56 Director Since March 2021 ... Mark J. Alvino currently serves as Chair of the Compensation Committee and as a member on the Audit Committee. ... Mark J. Alvino 65,000 271,143 - 336,143
2024-11-12	The table below represents the compensation paid to each of our directors who served on the Board during the year ended December 31, 2023.